Abstract
To identify cell-surface markers specific to human cardiomyocytes, we screened cardiovascular cell populations derived from human embryonic stem cells (hESCs) against a panel of 370 known CD antibodies. This screen identified the signal-regulatory protein alpha (SIRPA) as a marker expressed specifically on cardiomyocytes derived from hESCs and human induced pluripotent stem cells (hiPSCs), and PECAM, THY1, PDGFRB and ITGA1 as markers of the nonmyocyte population. Cell sorting with an antibody against SIRPA allowed for the enrichment of cardiac precursors and cardiomyocytes from hESC/hiPSC differentiationcultures, yielding populations of up to 98% cardiac troponin T-positive cells. When plated in culture, SIRPA-positive cells were contracting and could be maintained over extended periods of time. These findings provide a simple method for isolating populations of cardiomyocytes from human pluripotent stem cell cultures, and thereby establish a readily adaptable technology for generating large numbers of enriched cardiomyocytes for therapeutic applications.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Murry, C.E. & Keller, G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132, 661â680 (2008).
Kattman, S.J. et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8, 228â240 (2011).
Yang, L. et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453, 524â528 (2008).
Zwi, L. et al. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 120, 1513â1523 (2009).
Braam, S.R., Passier, R. & Mummery, C.L. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. Trends Pharmacol. Sci. 30, 536â545 (2009).
Anderson, D. et al. Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Mol. Ther. 15, 2027â2036 (2007).
Huber, I. et al. Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. FASEB J. 21, 2551â2563 (2007).
Ritner, C. et al. An engineered cardiac reporter cell line identifies human embryonic stem cell-derived myocardial precursors. PLoS ONE 6, e16004 (2011).
Hattori, F. et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat. Methods 7, 61â66 (2010).
Elliot, D.A. et al. Nat. Methods, advance online publication, doi:10.1038/nmeth.1740 (23 October 2011).
Seiffert, M. et al. Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. Blood 97, 2741â2749 (2001).
Timms, J.F. et al. SHPS-1 is a scaffold for assembling distinct adhesion-regulated multi-protein complexes in macrophages. Curr. Biol. 9, 927â930 (1999).
Subramanian, S., Parthasarathy, R., Sen, S., Boder, E.T. & Discher, D.E. Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood 107, 2548â2556 (2006).
Nostro, M.C. et al. Stage-specific signaling through TGFbeta family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells. Development 138, 861â871 (2011).
Park, I.H. et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141â146 (2008).
Matozaki, T., Murata, Y., Okazawa, H. & Ohnishi, H. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol. 19, 72â80 (2009).
Okazawa, H. et al. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J. Immunol. 174, 2004â2011 (2005).
Carvajal-Vergara, X. et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465, 808â812 (2010).
Itzhaki, I. et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471, 225â229 (2011).
Laflamme, M.A. et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25, 1015â1024 (2007).
Kisselbach, L., Merges, M., Bossie, A. & Boyd, A. CD90 Expression on human primary cells and elimination of contaminating fibroblasts from cell cultures. Cytotechnology 59, 31â44 (2009).
Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801â809 (1993).
Stevens, K.R. et al. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc. Natl. Acad. Sci. USA 106, 16568â16573 (2009).
Dvir, T. et al. Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Proc. Natl. Acad. Sci. USA 106, 14990â14995 (2009).
Lesman, A. et al. Transplantation of a tissue-engineered human vascularized cardiac muscle. Tissue Eng. Part A 16, 115â125 (2010).
Ling, Y., Maile, L.A., Lieskovska, J., Badley-Clarke, J. & Clemmons, D.R. Role of SHPS-1 in the regulation of insulin-like growth factor I-stimulated Shc and mitogen-activated protein kinase activation in vascular smooth muscle cells. Mol. Biol. Cell 16, 3353â3364 (2005).
Kennedy, M., D'Souza, S.L., Lynch-Kattman, M., Schwantz, S. & Keller, G. Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood 109, 2679â2687 (2007).
Costa, M. et al. A method for genetic modification of human embryonic stem cells using electroporation. Nat. Protoc. 2, 792â796 (2007).
Sharma, P., Shathasivam, T., Ignatchenko, V., Kislinger, T. & Gramolini, A.O. Identification of an FHL1 protein complex containing ACTN1, ACTN4, and PDLIM1 using affinity purifications and MS-based protein-protein interaction analysis. Mol. Biosyst. 7, 1185â1196 (2011).
Seiffert, M. et al. Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood 94, 3633â3643 (1999).
Acknowledgements
We would like to thank members of the Keller laboratory for discussion and critical reading of the manuscript, G. Daley (Harvard Medical School, Boston) for providing the MSC-iPS1 and 38-2 cell line, B. Neel for providing the Sirpa-mutant mice and for discussion and suggestions, L. Ailles, J. Paterson and E. Hyatt from the antibody core facility, R. Hamilton for assistance in obtaining fetal tissue samples and the Sick Kids/UHN Flow Cytometry Facility for their assistance with cell sorting. This work was supported by funding from VistaGen Therapeutics (San Francisco) and by grants from Canadian Institute of Health Research (CIHR, MOP-84524) and Ontario's Ministry of Research and Innovation (MRI, GL2-CBD3P3) to G.K. N.C.D. was supported by a Swiss National Foundation postdoctoral fellowship. A.G. and P.S. were supported by the Heart and Stroke Foundation of Ontario (T6281 and NS6636) and CIHR (MOP-106538). A.G.E., E.G.S. and D.A.E. are supported by grants from the Australian Stem Cell Centre, the National Health and Medical Research Council (NHMRC, Australia) and the National Heart Foundation (Australia). E.G.S. and A.G.E. are Senior Research Fellows of the NHMRC (Australia).
Author information
Authors and Affiliations
Contributions
N.C.D. and G.K. designed the study and wrote the paper. N.C.D., A.M.C., P.S. and A.G. designed and performed experiments and analyzed the data. D.A.E., A.G.E. and E.G.S. generated and provided the NKX2-5âGFP hESC line.
Corresponding author
Ethics declarations
Competing interests
G.K. is a paid consultant for, and N.B. and G.K. own stock in, VistaGen Therapeutics, which funded this study in part. N.C.B., A.M.C. and G.K. are employees of University Health Network, which has filed a patent application based on this study.
Supplementary information
Supplementary Text and Figures
Supplementary Tables 1â3 and Supplementary Figs. 1â12 (PDF 1843 kb)
Supplementary Movie 1
Embryoid bodies at day 20 derived from NKX2-5-GFP HES3 cells (MOV 1202 kb)
Supplementary Movie 2
Unsorted cardiac monolayer culture from HES2-derived EB's (MOV 20809 kb)
Supplementary Movie 3
Cardiac monolayer cultures from SIRPA+ sorted populations at day 20 (MOV 27410 kb)
Supplementary Movie 4
Cardiac monolayer cultures from SIRPA- sorted populations at day 20 (MOV 8154 kb)
Rights and permissions
About this article
Cite this article
Dubois, N., Craft, A., Sharma, P. et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol 29, 1011â1018 (2011). https://doi.org/10.1038/nbt.2005
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2005
This article is cited by
-
Surfaceome mapping of primary human heart cells with CellSurfer uncovers cardiomyocyte surface protein LSMEM2 and proteome dynamics in failing hearts
Nature Cardiovascular Research (2023)
-
Opportunities and challenges in cardiac tissue engineering from an analysis of two decades of advances
Nature Biomedical Engineering (2022)
-
Cardiac Cell Therapy with Pluripotent Stem Cell-Derived Cardiomyocytes: What Has Been Done and What Remains to Do?
Current Cardiology Reports (2022)
-
A dual cardiomyocyte reporter model derived from human pluripotent stem cells
Stem Cell Research & Therapy (2021)
-
ERRγ enhances cardiac maturation with T-tubule formation in human iPSC-derived cardiomyocytes
Nature Communications (2021)